CONCLUSIONS (Random Thoughts and Take Home Questions) gianluigi casadei
|
|
- Stephanie Hopkins
- 5 years ago
- Views:
Transcription
1 CONCLUSIONS (Random Thoughts and Take Home Questions) gianluigi casadei
2 IL SOLE 24 ORE (September 4, 2012)
3 Sustainability of health spending is a known issue for a long time The current crisis has dramatized it mainly in weak economies.
4 Appleby J. Can we afford the NIHS in future? BMJ 2011;343:d4321 doi: /bmj.d4321
5 The Burden of Health Care The ratio of total health expenditure (public and private) to GDP has at least doubled in countries with developed economy and welfare : more than half of the increase in primary expenditure (% of GDP) is attributable to health (G7: 57%) OECD and IMF: health expenditure expected to double in Pamolli F, Salerno NC. Sostenibilità e governance della spesa sanitaria. Roma, 6/12/2010
6 3 2 1 Biacker K, Chernew ME. The Economics of Financing Medicare. NEJM, 13/7/2011
7 Supporting Sustainability Increasing fiscal pressure Cost saving measures Cutting services (delayed/difficult access, outsourcing, ) Copayment
8 Out-of-pocket Health Expense pro capita ($ PPA) OECD Health Data
9 Italy: The Burden of Co-payment Sources: AIFA. Annual reports on national drug consumption.
10 Is this road feasible further? Is the end of the universal health coverage? Should we move toward a Bismarckian-like model?
11 o Three patients suffering from metastatic GI cancer o From 2001 enrolled in the imatinib phase III program o Sustained responses for 8 years. o Then, treatment discontinued due to economic downturn
12 Supporting Sustainability Avoid (minimize) waste This waste is more than 1.5 times the nation s total infrastructure investment in 2004, including roads, railroads, aviation, drinking water, telecommunications, and other structures. Source: Best Care at Lower Cost: The Path to Continuously Learning Health Care in America, Institute of Medicine.
13 Digital infrastructure 2012 Italian Investment pro capita: 22 (UK: 60; F: 40; D: 36) Payment-by-Performance Arch Intern Medicine September 4, 2012 Politecnico di Milano, 2012.
14 Decentralization: Looking for the Efficiency Pamolli F, Salerno NC. Le differenze regionali nella governance della spesa sanitaria ISQ Helath Quality Index (Outcome* 0,5 + Satisfaction * 0,17 + Medical Tourism * 0,17 + Hospitalization risk * 0,17)
15 Decentralization (Regionalism) Should (could) we still afford it? Region 2008 net expediture* Net cost per capita Mean standard cost Standard budget* Piemonte ,60 V. d Aosta ,60 Lombardia ,10 Pa Bolzano ,70 Pa Trento ,80 Veneto ,70 Friuli V.G ,10 Liguria ,30 Emilia R ,10 Toscana ,00 Umbria ,70 Marche ,90 Lazio ,50 Abruzzo ,50 Molise ,70 Campania ,00 Puglia ,40 Basilicata ,40 Calabria ,40 Sicilia ,60 Sardegna ,10 Standard vs. net* Total ,10 Pamolli F, Salerno NC. Le differenze regionali nella governance della spesa sanitaria. 2011
16 Innovation is There is no shortage of definitions of innovation. It will come as no surprise that, while everyone was content to use the word, and everyone agreed that it was a good thing, it was not easy to identify what was being discussed. In fact, as is common in policy-making, the absence of any hard centre of meaning allows people from all quarters to appear to be in agreement, without the need to nail down what it is that they were agreed on. Kennedy I: Appraising the value of innovation and other benefits. A short study for NICE Sir Ian Kennedy (2009)
17 Lack of an active arm (best available alternative) Add on therapy Primary efficacy criteria based on clinical assessment Follow-up (often) insufficient Additional benefit difficult to assess Simply new or innovative? Higher cost is the only certainty
18 Costs in Cancer Care Direct costs in US $ 104 billion in 2006 $ 173 billion in due to increases of: number of treated patients, therapies per each patients, cost per treatment. Sales of cancer drugs ranks 2 nd after cardiovascular drugs Monthly cost $ Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Eng J Med 2011; 364:2060-5
19 Costs in Cancer Care Their continued growth is no longer sustainable We must find ways to reduce the costs of everyday care to allow more people and advances to be covered without bankrupting the health care system. Medical oncologists directly or indirectly control or influence the majority of cancer care costs, including the use and choice of drugs, the types of supportive care, the frequency of imaging, and the number and extent of hospitalizations. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Eng J Med 2011; 364:2060-5
20 Behaviour Approach Practice Diagnostic only when FU is beneficial Sequential monotheraphy in 2 nd and 3 rd line Chemio only if performance status is high 4 th line only with investigational drugs Set realistic targets - expectations Cognitive approach Palliative care Know and accept current limits Improve Resource Allocation Elaborato da: Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Eng J Med 2011; 364:2060-5
21 Profitability Always target a high price Should (could) profitability balanced with sustainability?
22 Pollack A. New drugs fight prostate cancer, but at high cost. The New York Times, 27/6/2011
23 Pollack A. New drugs fight prostate cancer, but at high cost. The New York Times, 27/6/ May I afford it?
24 Lapatinib NICE (2010) Appraising treatments that may extend the life of patients with a short life expectancy and that are licensed for indications that affect small numbers of people with incurable illnesses Lapatinib ICER per QALY gained Survival extended for less than 2.4 months No evidence of any subgroup of patients who may have an incremental benefit. F. Hoffmann-La Roche Ltd., Group Communications NICE Guidance (6/2010) Lapatinib
25 4 CONSIDERATION OF THE EVIDENCE 4.2 The Committee heard from the clinical specialists that ipilimumab represents a step change in the treatment of advanced melanoma and is the first new treatment available in 30 years that may offer significant palliation and possible survival gain for people with advanced, unresectable disease that has progressed after first-line therapy. 4.3 The Committee heard from the clinical specialists that approximately 30% of people treated with ipilimumab will have improved survival, and about 10% of people may have longterm benefits. The clinical specialists indicated that melanoma may have an unpredictable clinical course and that late recurrences are well recognised. fewer than 1% of patients in the ipilimumab arms showed a complete disease response.
26 Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol Dec 10;27(35): Epub 2009 Oct 13.
27 Progression Free Survival PFS x 2 Modified from Sobrero A, Bruzzi P. J Clin Oncol Dec 10;27(35): PFS +50% 10 mos 5 mos Breast, ovary, colonrectum PFS 5-10 months MST 2 years MST +30% Pancreas, Gastric, NSCLC PFS 2-4 mos MST < 1 year MST +50% Median Survival Time years
28 Value-Based Pricing The setting of a product or service's price, based on the benefits it provides to consumers. Have Health Authorities the right (and duty) to set thresholds to define what progress (innovation) is? Should the EMA assess also the expected additional benefit of a new (innovative) drug? Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009; 338:b1025
29 Gracias por su atención
The Italian decision to mandate. children vaccinations. Fortunato D Ancona, MD Italian Ministry of Health
The Italian decision to mandate children vaccinations Fortunato D Ancona, MD Italian Ministry of Health The ASSET FINAL EVENT Share and move for mobilization and mutual learning at local, national and
More informationPDTA: assistential and diagnostic-therapeutic paths
PDTA: assistential and diagnostic-therapeutic paths Salvatore Leone Amici Onlus, National Coalition of Associations for Patients suffering Chronic Diseases (CnAMC), Italy What is IBD? Crohn s disease and
More informationL USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO
AISF-SIMTI POSITION PAPER - L USO APPROPRIATO DELL ALBUMINA Roma, 29 marzo 2016 L USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO Mauro Bernardi Semeiotica Medica Dipartimento di Scienze Mediche
More informationStatistical Table 20: Prevalence of antibodies against hepatitis B virus among injecting drug users in the EU (sample sizes in brackets)
Belgium, French Community 23.5 (5 23.8 (240 20.0 (95 5.7 (27 SR selfreported test results; > 80% missing data. Belgium, Flemish Community 7.9 (06 20.0 (55 2.7 (57 5.0 (33 7. (3 AHBs. Drug, 2 Belgium, Flemish
More informationPriority actions of the different Regional Prevention Plans: common features and innovations
Priority actions of the different Regional Prevention Plans: common features and innovations Francesca Russo (1), Federica Michieletto (1), Annarosa Pettenò (1), Chiara Postiglione (2), Giuseppina Napoletano
More informationMarina Davoli Department of Epidemiology Lazio Region/Italian National Agency for Regional Health Services
Marina Davoli Department of Epidemiology Lazio Region/Italian National Agency for Regional Health Services Main objectives of the PNE include: comparative evaluation among healthcare providers; comparative
More informationItalian Observatory on Healthcare Report 2014 Health status and quality of care in the Italian Regions
Italian Observatory on Healthcare Report 2014 Health status and quality of care in the Italian Regions Summary by Dr. Alessandro Solipaca e Dr. Marta Marino Osservasalute Report 2013 Summary Since 12 years,
More informationSpecial Olympics Family Leadership and Support. Family Program Example Special Olympics Italy
Special Olympics Family Leadership and Support Family Program Example Special Olympics Italy Special Olympics vision The new strategic plan Families are asked to become COMMUNITY BUILDERS National Organizing
More informationPAIN makes a difference
PAIN makes a difference 1 yester day. large problem small solutions 2 not just compassion. 3 opioid consumption 2006!0.35 National healthcare service per capita disbursement 4 opioid consumption 2007!0.67
More informationA standardization study of the Italian version of Frenchay Aphasia Screening Test in aphasic patients and control subjects
9 th European Congress of Speech and Language Therapy Palazzo dei Congressi & Palazzo degli Affari, Florence, Italy 8/9 May 2015 A standardization study of the Italian version of Frenchay Aphasia Screening
More informationWhat Does Breast Cancer Treatment Cost and What Is It Worth?
What Does Breast Cancer Treatment Cost and What Is It Worth? Elena B. Elkin, PhD Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center Is This Drug Worth the Cost? Ixabepilone added
More informationAn Italian survey on the attitudes in treating breakthrough cancer pain in hospice
Support Care Cancer (2011) 19:979 983 DOI 10.1007/s00520-010-0919-5 ORIGINAL ARTICLE An Italian survey on the attitudes in treating breakthrough cancer pain in hospice Sebastiano Mercadante & Patrizia
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationABRCAdaBRA:Opening the Way to Women with a BRCA Mutation in Italy. Ornella Campanella February 5, 2016
ABRCAdaBRA:Opening the Way to Women with a BRCA Mutation in Italy Ornella Campanella February 5, 2016 Who we are? Everythings was born on Facebook two years ago. Then we met in Pavia during the 4 Pavia
More informationValue Based Health Care in the UK: NICE, VBP and the Cost-effectiveness Threshold. Eldon Spackman, MA, PhD
Value Based Health Care in the UK: NICE, VBP and the Cost-effectiveness Threshold Eldon Spackman, MA, PhD Background to NICE NICE s current position on the threshold Two concepts of the threshold Why the
More informationTechnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 NICE 2018. All rights
More informationMellar P Davis MD FCCP FAAHPM Director of Palliative Services Geisinger Medical Center
Mellar P Davis MD FCCP FAAHPM Director of Palliative Services Geisinger Medical Center Communication and collusion Early palliative care embedded into palliative oncology Outcomes to palliative oncology
More informationINCREASING VACCINATION IN CHILDREN. Susanna Esposito
INCREASING VACCINATION IN CHILDREN Susanna Esposito Pediatric Highly Intensive Care Unit, University of Milan, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy DISCLOSURE OF INTEREST
More informationScreening di Popolazione. del Cancro Colorettale. C. Hassan
Screening di Popolazione del Cancro Colorettale C. Hassan The Present 1. Organized screening program - Active invitation (less inequality) - Rapid coverage of the target population (2 yrs) - Quality Assurance
More informationTechnology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December
More information2nd International Expert Meeting on Gluten Sensitivity Munich, December 1st 2012
2nd International Expert Meeting on Gluten Sensitivity Munich, December 1st 2012 NON CELIAC GLUTEN SENSITIVITY IN ADULTS: CLINICAL AND SEROLOGICAL ASPECTS Umberto Volta Coeliac Disease and Malabsorption
More informationHealth Technology Assessment and the Demands of the Fourth Hurdle Experiences from TLV in Sweden
1 Health Technology Assessment and the Demands of the Fourth Hurdle Experiences from TLV in Sweden Ulf Persson IHE, The Swedish Institute for Health Economics & Institute of Economic Research, School of
More informationTechnology appraisal guidance Published: 7 March 2018 nice.org.uk/guidance/ta509
Pertuzumab with trastuzumab and docetaxel el for treating HER2-positive breast cancer Technology appraisal guidance Published: 7 March 20 nice.org.uk/guidance/ta509 NICE 20. All rights reserved. Subject
More informationPrEPararsi alla PrEP: indagine sulla propensione dei medici di malattie infettive
UOC Infezioni emergenti e Centro di riferimento AIDS Dipartimento di Epidemiologia Istituto Nazionale per le Malattie Infettive L. Spallanzani - IRCCS, Rome, Italy Profilassi con antiretrovirali pre- e
More informationAim of the project. costs/expenditure, output, productivity, health outcomes, 1 The main aim of this project is to provide a quantitative analysis on:
Aim of the project 1 The main aim of this project is to provide a quantitative analysis on: costs/expenditure, output, productivity, health outcomes, of the Italian health care system based on patient
More informationOncology Management at HAP. John Calabria, DO, Medical Director
Oncology Management at HAP John Calabria, DO, Medical Director Agenda Rising Cost of Health Care Ways of Managing Oncology Cost Pathways Update Where do we go from here? The Cost of Cancer Source: National
More informationPalliative Care A Tool for Transformation
Palliative Care A Tool for Transformation Rae Seitz, MD Kokua Mau Summit November 10, 2011 Today s Summit: A Call to Action Our healthcare systems requires change We, all of us, are the change agents Palliative
More informationTitle of the presentation
. Title of the presentation Economic analyses for hepatitis elimination Subtitle of the presentation, lorem ipsum dolor sit amet. Yvan Hutin, Global Hepatitis Programme, World Health Organization November
More informationCost-effectiveness, Affordability, and Financing of Cervical Cancer Prevention
Cost-effectiveness, Affordability, and Financing of Cervical Cancer Prevention Dr. Carol Levin PATH Video transcript is located below each slide. Cost-effectiveness, Affordability, and Financing of Cervical
More informationKey Messages for World Malaria Day 2009
INFORMATION RBM/WG/2009/INF.12 10 APR 2009 Draft document General distribution English Only Key Messages for World Malaria Day 2009 Counting Malaria Out to Reaching the 2010 Targets On the occasion of
More informationPharmacoeconomics of Trastuzumab (Herceptin )
Pharmacoeconomics of Trastuzumab (Herceptin ) Breast Cancer Press Seminar (2008.3.3) Department of Health Economics and Epidemiology Research Graduate School of Medicine, The University of Tokyo Takashi
More informationCan you bring these to the attention of the committee when it meets. I hope to be there, and will gladly talk the committee trough them.
L Jeremy Powell NICE By Email 17 th Aug 2011 Dear Jeremy, Thank you for the opportunity to contribute to this TA. I have forwarded to NICE the necessary paperwork including our comment form. I have a number
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395
Ceritinib for previously treated anaplastic lymphoma kinase positive non- small-cell lung cancer Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta5 NICE 2018. All rights reserved.
More informationMeltdown : Investing in Prevention. October 7, 2008
Averting a Health Care Meltdown : Investing in Prevention October 7, 2008 Agenda Introductory Remarks Featured Speakers Wendy E Braund, MD, MPH, MSEd, 11th Luther Terry Fellow & Senior Clinical Advisor
More information+ Economic Analyses in Clinical
+ Economic Analyses in Clinical Trials Nicole Mittmann (and Natasha Leighl) Committee on Economic Analysis (formerly, Working Group on Economic Analysis, NCIC CTG) Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca
More informationTransforming Health Care in Missouri: National and Historical Context. Robert Hughes, PhD October 13, 2017
Transforming Health Care in Missouri: National and Historical Context Robert Hughes, PhD October 13, 2017 Setting the Context 1. What is the current state of U.S. and Missouri health care? 2. How did we
More informationTrust Your Employees Smiles to Delta Dental
Trust Your Employees Smiles to Delta Dental #SGEB2019 Give Employees Something to Smile About Employees rate dental benefits second in importance when comparing insurance coverage. According to the Delta
More informationMaking Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK Outline Policy context
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Technology Appraisals. Patient Access Scheme Submission Template
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Technology Appraisals Patient Access Scheme Submission Template Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line
More informationValue Based Reimbursement Do we want it? Do we already have it? CADTH Symposium Vancouver, April 2011
Value Based Reimbursement Do we want it? Do we already have it? CADTH Symposium Vancouver, April 2011 David Shum, PharmD, MBA Director, Reimbursement & Health Economics Roche Pharmaceuticals Agenda 1.
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationTechnology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE
More informationRealigning Reimbursement Policies for Quality and Value in Cancer Care
Realigning Reimbursement Policies for Quality and Value in Cancer Care Jennifer Malin, MD, PhD Medical Director, Oncology Solutions and Innovation Pay for Performance Summit Mini-Summit V: Innovative Payment
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationInsurance Guide For Dental Healthcare Professionals
Insurance Guide For Dental Healthcare Professionals Dental Benefits Basics What is dental insurance? Unlike traditional insurance, dental benefits are not meant to cover all oral healthcare needs. The
More information2013 Memorial Sloan-Kettering Cancer Center, All Rights Reserved.
Cost Effectiveness and Cancer Rehabilitation Andrea L Cheville, MD, MSCE Associate Professor and Research Chair Department of Physical Medicine and Rehabilitation Mayo Clinic, Rochester Why cost matters
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationTHE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER
THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER INTERNATIONAL HEALTH International health has been seen as
More informationBLUETONGUE IN ITALY: RISK ANALYSIS ON THE INTRODUCTION INTO FREE TERRITORIES OF VAC- CINATED ANIMALS FROM RE- STRICTED ZONES.
BLUETONGUE IN ITALY: RISK ANALYSIS ON THE INTRODUCTION INTO FREE TERRITORIES OF VAC- CINATED ANIMALS FROM RE- STRICTED ZONES. Bruxelles, 3 Dicembre 2002 INTRODUCTION...1 Italian strategy against bluetongue...
More informationMeeting the MDGs in South East Asia: Lessons. Framework
Meeting the MDGs in South East Asia: Lessons and Challenges from the MDG Acceleration Framework Biplove Choudhary Programme Specialist UNDP Asia Pacific Regional Centre 21 23 23 November 2012 UNCC, Bangkok,
More information2018 Candidate Guide. Leading in the fight to end Alzheimer's
2018 Candidate Guide Leading in the fight to end Alzheimer's Table of Contents Candidate Letter...2 2018 Alzheimer's Disease Facts and Figures...3 Federal Policies to Lead on Alzheimer's...4 State Policies
More informationNational Dental Expenditure Flat Since 2008, Began to Slow in 2002
National Dental Expenditure Flat Since 2008, Began to Slow in 2002 Author: Marko Vujicic, Ph.D. The Health Policy Institute (HPI) is a thought leader and trusted source for policy knowledge on critical
More informationProfessor Karl Claxton, Centre for Health Economics, University of York
Welcome to the InstEAD Annual Lecture 2014 Professor Karl Claxton, Centre for Health Economics, University of York Health (and ethics) Needs Economics: Which Health Technologies, at What Price and for
More informationMethods for the Estimation of the NICE Cost Effectiveness Threshold
Methods for the Estimation of the NICE Cost Effectiveness Threshold Karl Claxton, 1,2 Steve Martin, 2 Marta Soares, 1 Nigel Rice, 1,2 Eldon Spackman, 1 Sebastian Hinde, 1 Nancy Devlin, 3 Peter C Smith,
More informationPart 1 Public handouts
Part 1 Public handouts Chair s presentation Trastuzumab emtansine for treating HER2- positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane Rapid
More informationEvidence based assessment of the value of innovation: pricing solutions and prospects
Evidence based assessment of the value of innovation: pricing solutions and prospects Karl Claxton 7/11/2017 How much can we pay for innovation? Cost Price > P* 60,000 30,000 per QALY Cost-effectiveness
More informationMethods for the Estimation of the NICE Cost Effectiveness Threshold
Methods for the Estimation of the NICE Cost Effectiveness Threshold Karl Claxton, 1,2 Steve Martin, 2 Marta Soares, 1 Nigel Rice, 1,2 Eldon Spackman, 1 Sebastian Hinde, 1 Nancy Devlin, 3 Peter C Smith,
More informationAccess to cancer drugs: The role for a stakeholder alliance?
Access to cancer drugs: The role for a stakeholder alliance? John Zalcberg Co-Chair, Cancer Drugs Alliance (CDA) Disclosures Research support, travel support and honoraria from a wide variety of pharmaceutical
More informationAn Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Kevin Klowden Managing Economist Milken Institute (310) 570
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationPalliative Care in the Continuum of Oncologic Management
Palliative Care in the Continuum of Oncologic Management PC in the Routine Continuum of Cancer Care Michael W. Rabow, MD Director, Symptom Management Service Helen Diller Family Comprehensive Cancer Center
More informationResponse to HIV LOGISTICAL AND OTHER PERSPECTIVES
Response to HIV LOGISTICAL AND OTHER PERSPECTIVES Margaret Brandeau Department of Management Science and Engineering Department of Medicine Stanford University Topics HIV: A humanitarian crisis Planning
More informationTechnology appraisal guidance Published: 12 December 2012 nice.org.uk/guidance/ta269
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma Technology appraisal guidance Published: 12 December 2012 nice.org.uk/guidance/ta269 NICE 2018. All
More informationTechnology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487
Venetoclax for treating chronic lymphocytic leukaemia Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCancer Control Joint Action, Improving Outcomes for Cancer Patients and the European Cancer Patient s Bill of Rights
Cancer Control Joint Action, Improving Outcomes for Cancer Patients and the European Cancer Patient s Bill of Rights Second CANCON Stakeholder Forum 12 May 2015 Belgian Ministry of Health, Brussels EQUITY
More informationYou Get What You Pay For The Unintended Consequences of Buy and Bill in Oncology
You Get What You Pay For The Unintended Consequences of Buy and Bill in Oncology Jeffrey Peppercorn, MD, MPH Associate Professor of Medicine Director, Cancer Survivorship Center Duke Cancer Institute Duke
More informationPharmaco-economic aspects of in-vitro fertilization in Italy Mantovani L G, Belisari A, Szucs T D
Pharmaco-economic aspects of in-vitro fertilization in Italy Mantovani L G, Belisari A, Szucs T D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More information10.2 Summary of the Votes and Considerations for Policy
CEPAC Voting and Policy Implications Summary Supplemental Screening for Women with Dense Breast Tissue December 13, 2013 The last CEPAC meeting addressed the comparative clinical effectiveness and value
More informationNAMIBIA INVESTMENT CASE
NAMIBIA INVESTMENT CASE OUTLINE Why an Investment Case for HIV Response in Namibia? Investment Scenarios Can we achieve Fast Track and End AIDS as public health threat by 2030? Can we afford it? Efficiencies:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationNICE appraisal consultation document for teriflunomide [ID548]
NICE appraisal consultation document for teriflunomide [ID548] Response from the Multiple Sclerosis Trust 9 th October 2013 Please find below comments from the MS Trust in relation to the Appraisal Consultation
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 NICE 2017. All rights reserved. Subject
More informationlimitations of the indirect evidence submitted to pcodr, perc concluded that there is considerable uncertainty on how alectinib compares with ceritinib with regard to outcomes important to decision making
More informationClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015 ClinicalTrials.gov ID: NCT01378962 Study Identification Unique Protocol ID: ML25514 Brief Title: A Study
More informationCancer Care Quality Program. Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015
Cancer Care Quality Program Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015 Off-Label Use Disclosure I do not intend to discuss an off-label use of a product during
More informationIntroduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY
MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)
More informationOECD S HEALTH AT A GLANCE 2015 WHAT INSIGHTS FOR THE UK? Mark Pearson, Deputy Director Directorate for Employment, Labour and Social Affairs
OECD S HEALTH AT A GLANCE 2015 WHAT INSIGHTS FOR THE UK? Mark Pearson, Deputy Director Directorate for Employment, Labour and Social Affairs Health at a Glance 2015 How does the UK perform? A leader in
More informationIntroduction to Cost-Effectiveness Analysis
Introduction to Cost-Effectiveness Analysis Janie M. Lee, MD, MSc RSNA Clinical Trials Methodology Workshop January 13, 2016 Why is Clinical Research Important to Radiology? Radiology currently occupies
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
More informationDo medical oncologists and cancer patients care about treatment costs of systemic anticancer therapy?
JBUON 2015; 20(6): 1606-1611 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Do medical oncologists and cancer patients care about treatment costs
More informationTechnology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357 NICE 2018. All rights reserved.
More informationFoundations in Community-Based Palliative Care Essential Elements for Success
Foundations in Community-Based Palliative Care Essential Elements for Success Presented by Russell K Portenoy MD Foundations in Community-Based Palliative Care Essential Elements for Success Russell K
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationUpdate of the universal vaccination programme in Italy
Update of the universal vaccination programme in Italy Progress in the prevention and control of hepatitis B in Italy, 12 years after the implementation of universal vaccination. Duration of immunity and
More informationDefinition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision
Scott Ramsey, MD, PhD Definition Trials for which the hypothesis and study design are formulated based on information needed to make a decision Synonyms Pragmatic clinical trials Practical clinical trials
More informationTechnology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239
Fulvestrant for the treatment of locally advanced or metastatic breast cancer Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239 NICE 2018. All rights reserved. Subject
More informationTechnology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516
Cabozantinib for treating medullary thyroid cancer Technology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAn Italian experience of training teachers* under the School Fruit and Vegetables Scheme
An Italian experience of training teachers* under the School Fruit and Vegetables Scheme Laura Gennaro Research Centre for Food and Nutrition (CREA-AN) laura.gennaro@crea.gov.it *Project funded by the
More informationSummary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS
A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OCTOBER 2018 Summary CASTRATION-RESISTANT PROSTATE CANCER Prostate cancer is the second most common cause of cancer
More informationWhat do the new evolutions in GI cancer mean for my practices
What do the new evolutions in GI cancer mean for my practices South (and Latin) America view Jorge Gallardo MD Medical Oncologist Santiago de Chile. «SLAGO working group» Chilean Foundation for Development
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationMANAGED DENTAL CARE: PRACTICE OF DENTISTRY. Overview of Benefit Issues. Changes in the Delivery of Dental Benefits FEE-FOR-SERVICE
Managed Care: Dentistry June 25, 23 PRACTICE OF DENTISTRY (BUSINESS ASPECT) VS. Overview of Benefit Issues PRACTICING DENTISTRY (PROFESSIONAL ASPECT) Changes in the Delivery of Dental Benefits Indemnity
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationPriority setting at a national level NICE - England. Gillian Leng Deputy Chief Executive, NICE September 2016
Priority setting at a national level NICE - England Gillian Leng Deputy Chief Executive, NICE September 2016 Areas to cover The role of NICE in the UK health system General approach to appraising new drugs
More informationStatistical Table 13: Prevalence of HIV infection (%) among injecting drug users under age 25, in the EU (sample sizes between brackets)
Statistical Table 3: Prevalence of HIV infection (%) among injecting drug users under, in the EU (sample sizes between brackets) HIV IDUs under Belgium, French Community 99 992 993 994 995 996 997 998
More informationTechnology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183
Topotecan for the treatment of recurrent and stage IVB cervical cancer Technology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183 NICE 2018. All rights reserved. Subject to Notice
More information